Treatment Strategies in Mantle Cell Lymphoma-Reference-Cited by-同舟云学术

Treatment Strategies in Mantle Cell Lymphoma

Published:2015 Issue: Volume: Page:251-270
ISSN:0927-3042
Container-title:Non-Hodgkin Lymphoma
language:
Short-container-title:

Author:

Maddocks Kami,Blum Kristie A.

Publisher

Springer International Publishing

Link

http://link.springer.com/content/pdf/10.1007/978-3-319-13150-4_10

Reference57 articles.

1. Swerdlow S, Campo E, Harris N et al (2008) WHO classification of tumors of hematopoietic and lymphoid tissues. World Health Organization, Lyon, pp 229–232

2. Anderson JR, Armitage JO et al (1998) Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s lymphoma classification project. Ann Oncol 9(7):717–720

3. Zhou Y, Wang H et al (2008) Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancerb 113(4):791–798

4. International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994

5. Hoster E, Dreyling M, Klapper W et al (2008) A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma. Blood 111:558–565

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First Report of FARSA in the Regulation of Cell Cycle and Survival in Mantle Cell Lymphoma Cells via PI3K-AKT and FOXO1-RAG1 Axes;International Journal of Molecular Sciences;2023-01-13

2. A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas;Journal of Clinical Investigation;2022-12-15

3. 3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma;Cancer Cell International;2021-05-26

4. Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma;Human Pathology;2019-11

5. Consolidation with 90Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up;Leukemia & Lymphoma;2019-04-09